Literature DB >> 10329565

Genetic recombination of poliovirus in vitro and in vivo: temperature-dependent alteration of crossover sites.

R Duggal1, E Wimmer.   

Abstract

Genetic recombination that occurs with high frequency during poliovirus genome replication is a process whose molecular mechanism is poorly understood. Studies of genetic recombination in a cell-free system in vitro and in infected tissue culture cells in vivo have led to the unexpected observation that temperature strongly influences the loci at which cross-over between the two recombining RNA strands occurs. Specifically, cross-over between two genetically marked RNA strands in vitro and in vivo at 34 degrees C occurred over a wide range of the genome. In contrast, recombination in vivo at 37 and 40 degrees C yielded cross-over patterns that had shifted dramatically to a region encoding nonstructural proteins. Preferential selection of recombinants at 37 and 40 degrees C was ruled out by analyses of the growth kinetics of the recombinants. During the studies of recombination in the cell-free system we found that there is a direct correlation between the ability of a poliovirus RNA molecule to replicate in the cell-free system and its capacity to complement de novo virus synthesis programmed by another viral RNA. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329565     DOI: 10.1006/viro.1999.9703

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Comparison of classic and molecular approaches for the identification of untypeable enteroviruses.

Authors:  M S Oberste; K Maher; M R Flemister; G Marchetti; D R Kilpatrick; M A Pallansch
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

2.  Snow Mountain virus genome sequence and virus-like particle assembly.

Authors:  Vance P Lochridge; Michele E Hardy
Journal:  Virus Genes       Date:  2003-01       Impact factor: 2.332

3.  Recombination of poliovirus RNA proceeds in mixed replication complexes originating from distinct replication start sites.

Authors:  Denise Egger; Kurt Bienz
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Molecular identification and analysis of nonserotypeable human enteroviruses.

Authors:  Fei Zhou; Fanrong Kong; Kenneth McPhie; Mala Ratnamohan; Gwendolyn L Gilbert; Dominic E Dwyer
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

5.  Evolution of 2B and 2C genomic parts of species B Coxsackie viruses. Phylogenetic study and comparison with other regions.

Authors:  Eugenia Bolanaki; Christine Kottaridi; Panayotis Markoulatos; Lukas Margaritis; Theodoros Katsorchis
Journal:  Virus Genes       Date:  2006-06       Impact factor: 2.332

6.  Poliovirus protein 3AB displays nucleic acid chaperone and helix-destabilizing activities.

Authors:  Jeffrey J DeStefano; Oduyebo Titilope
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  The twenty-nine amino acid C-terminal cytoplasmic domain of poliovirus 3AB is critical for nucleic acid chaperone activity.

Authors:  Divya R Gangaramani; Elizabeth L Eden; Manthan Shah; Jeffrey J Destefano
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

8.  Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees.

Authors:  N S Cuervo; S Guillot; N Romanenkova; M Combiescu; A Aubert-Combiescu; M Seghier; V Caro; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

9.  Recombination in circulating enteroviruses.

Authors:  Alexander N Lukashev; Vasilii A Lashkevich; Olga E Ivanova; Galina A Koroleva; Ari E Hinkkanen; Jorma Ilonen
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Evidence that the linker between the methyltransferase and helicase domains of potato virus X replicase is involved in homologous RNA recombination.

Authors:  Heidrun-Katharina Draghici; Mark Varrelmann
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.